Breeze Holdings Acquisition Corp. Provides Update on Trading Status and Potential Business Combination

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Aug 21 2024

0mins

BREZ0%

Explore Agentic TradingLet AI Trade for You

Source: Newsfilter

Breeze Holdings Acquisition Corp. Trading Update: Breeze Holdings has received approval to trade on the OTCQX Best Market, with its common stock and warrants now available under the tickers "BRZH" and "BRZHW" as of August 21, 2024.
Business Combination Plans: Following the termination of a business combination with TV Ammo, Inc., Breeze intends to pursue other potential business combinations, with a deadline set by the SEC for completion by December 26, 2024.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BREZ?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on BREZ

Wall Street analysts forecast BREZ stock price to rise

0 Analyst Rating

0 Buy

0 Hold

0 Sell

Current: 9.915

Low

Averages

High

Current: 9.915

Low

Averages

High

No data

About BREZ

Breeze Acquisition Corp. II is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus its search on companies with global operations and differentiated technology or capabilities, particularly in healthcare, biotechnology, advanced manufacturing, robotics, artificial intelligence, and related sectors. The Company has not generated any operating revenues.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Breeze Acquisition Corp. II Prices IPO at $10 per Unit

May 13 2026Newsfilter

IPO Pricing Announcement: Breeze Acquisition Corp. II has priced its initial public offering of 12,500,000 units at $10.00 per unit, with trading expected to commence on May 13, 2026, indicating strong market confidence in its future business combinations.
Unit Composition and Trading: Each unit consists of one ordinary share and one right, with rights allowing holders to receive one-fifth of an ordinary share upon the completion of a business combination, designed to attract investors and enhance market appeal.
Underwriters and Over-Allotment: IB Capital LLC and I-Bankers Securities, Inc. are acting as book-running managers, with underwriters granted a 45-day option to purchase up to 1,875,000 additional units, reflecting strong demand for the offering.
Use of Proceeds and Strategic Focus: The net proceeds from the offering will be utilized to fund business combinations with companies having global operations and differentiated technologies, particularly in healthcare, biotechnology, and artificial intelligence, highlighting the company's focus on high-growth sectors.

Breeze Holdings Acquisition Corp. Shareholders Approve Business Combination with YD Biopharma Limited

Aug 15 2025Newsfilter

Business Combination Approval: Breeze Holdings Acquisition Corp. has received stockholder approval for its business combination with YD Biopharma Limited, a Taiwan-based biopharmaceutical company, and the new entity will be named YD Bio Limited, expected to trade on Nasdaq under the ticker symbol "YDES."
Company Focus and Future Plans: YD Biopharma is dedicated to developing innovative vaccines and therapeutics for infectious diseases and aims to transform treatment options for various high unmet medical needs, with the transaction expected to close within two weeks.

Breeze Holdings Acquisition Corp. Announces Definitive Agreement to Merge with YD Biopharma Limited

Sep 25 2024Newsfilter

Proposed Merger: YD Biopharma is set to merge with Breeze Holdings Acquisition Corp., aiming for a Nasdaq listing by early 2025, with an estimated enterprise value of nearly $700 million. The merger will enhance YD Biopharma's capabilities in cancer diagnostics and therapeutics.
Recent Developments: YD Biopharma has secured patents and U.S. authorization for advanced detection technologies for pancreatic and breast cancer, expanding its product offerings and establishing a laboratory dedicated to early cancer detection.